JCO precision oncology · 2025
Optimized Biopsy Strategy for Transition Zone Prostate Cancer With Enhanced Perilesional Sampling: A Retrospective Analysis and Clinical Trial Validation.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xin, Huang Chen, Zhou Chenchao, Li Yu, Huang Renpeng, Bao Jie, Lin Yuxin, Truß Michael C, Hou Jianquan, Huang Yuhua, Wei Xuedong
Аннотация
PURPOSE: Prostate biopsy (PBx) is crucial for diagnosing prostate cancer (PCa). This study aims to identify potential underdiagnosis of transition zone (TZ) PCa compared with peripheral zone (PZ) tumors and validate a novel PBx strategy to improve TZ tumor detection.
MATERIALS AND METHODS: This study comprised two components: a retrospective analysis and a randomized clinical trial. The retrospective study included 217 patients who underwent radical prostatectomy after 8PZ + 4TZ + X transperineal transrectal ultrasound-magnetic resonance imaging-fusion PBx between 2018 and 2021. The clinical trial investigated biopsy efficacy in 400 patients who underwent either modified 8PZ + 10TZ + X PBx for the TZ lesion or 8PZ + 4TZ + X PBx after block random assignment between 2022 and 2023 at our center.
RESULTS: Retrospective analysis reveals identical TZ clinically significant prostate cancer (csPCa) detection rates for 8PZ + 4TZ + X and 4TZ + X PBx, both of which were insufficient for detecting TZ csPCa compared with PZ tumors. Based on these findings, 8PZ + 10TZ + X PBx was constructed. In the trial, the 10TZ + X and 8PZ + 10TZ + X PBx demonstrated identical TZ csPCa detection rates and biopsy positivity rate, outperforming the 4TZ + X and 8PZ + 4TZ + X PBx without increasing complications. The self-controlled comparison showed equivalent results for 8TZ + X and 8PZ + 10TZ + X PBx.
CONCLUSION: Our study found that PZ biopsies offer no additional benefit for TZ lesion tumors, and increasing the number of cores in the TZ region can compensate for the current limitations of TZ biopsies. These findings provide potential avenues for optimizing biopsy strategies for TZ lesions.
MATERIALS AND METHODS: This study comprised two components: a retrospective analysis and a randomized clinical trial. The retrospective study included 217 patients who underwent radical prostatectomy after 8PZ + 4TZ + X transperineal transrectal ultrasound-magnetic resonance imaging-fusion PBx between 2018 and 2021. The clinical trial investigated biopsy efficacy in 400 patients who underwent either modified 8PZ + 10TZ + X PBx for the TZ lesion or 8PZ + 4TZ + X PBx after block random assignment between 2022 and 2023 at our center.
RESULTS: Retrospective analysis reveals identical TZ clinically significant prostate cancer (csPCa) detection rates for 8PZ + 4TZ + X and 4TZ + X PBx, both of which were insufficient for detecting TZ csPCa compared with PZ tumors. Based on these findings, 8PZ + 10TZ + X PBx was constructed. In the trial, the 10TZ + X and 8PZ + 10TZ + X PBx demonstrated identical TZ csPCa detection rates and biopsy positivity rate, outperforming the 4TZ + X and 8PZ + 4TZ + X PBx without increasing complications. The self-controlled comparison showed equivalent results for 8TZ + X and 8PZ + 10TZ + X PBx.
CONCLUSION: Our study found that PZ biopsies offer no additional benefit for TZ lesion tumors, and increasing the number of cores in the TZ region can compensate for the current limitations of TZ biopsies. These findings provide potential avenues for optimizing biopsy strategies for TZ lesions.